Subscribe to RSS - Inogen


Inogen cleared for reimbursement in France


GOLETA, Calif. – The Inogen One G3 portable oxygen concentrator has received coverage for reimbursement in France, the company announced Sept. 9.

Inogen reports big gains, improves outlook


GOLETA, Calif. – Inogen’s focus on direct-to-consumer sales is paying off, CEO Ray Huggenberger says.

Inogen repeats double-digit increase


Inogen repeats double-digit increase

GOLETA, Calif. – Inogen increased total revenues 50.8% in the second quarter of 2014, the company reported this week.

People news


Dave Cormack, president and CEO of Brightree, has been elected to the AAHomecare board of directors.

Inogen makes play in stationary market


GOLETA, Calif. – Inogen has received clearance from the U.S. Food and Drug Administration (FDA) for a home oxygen concentrator called Inogen At Home.

Embrace 'rapid maturity' of oxygen market


Whether an oxygen provider won the second round of Medicare competitive bidding or not, the results are the same: a dramatic restructuring of the oxygen business model is necessary for continued viability in the category, market experts say.

Inogen off to ‘strong start’ in 2014


GOLETA, Calif. – The first quarter of the year is seasonably slow for many public companies, but not this year, not for Inogen.

Short takes: Brightree, Inogen, Roscoe Medical


Atlanta-based Brightree has launched Brightree Home Infusion, a new solution to address the clinical, operational and billing needs of home infusion pharmacies.

Inogen reports double-digit increases


GOLETA, Calif. – The impact of competitive bidding is “pretty much behind us,” Inogen President and CEO Raymond Huggenberger said during the company’s first-ever earnings call on March 27.

INGN opens for trading


GOLETA, Calif. – Inogen (INGN) opened for trading on the NASDAQ on Feb. 14, pricing about 4.4 million shares of its stock at $16 per share, the low end of an expected range of $16 to $18. On Feb. 18, the company’s stock was trading at $15.28 per share.